doi:https://doi.org/

References:

Thiele H., Akin I., Sandri M., et al. PCI strategies in patients with acute myocardial infarction and cardiogenic shock. N Engl J Med 2017;377:2419—2432.
Ibanez B., James S., Agewall S., et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018;39:119—177.
Levy B., Bastien O., Benjelid K., et al. Experts’ recommendations for the management of adult patients with cardiogenic shock. Ann Intensive Care 2015;5:52.
Katz J.N., Stebbins A.L., Alexander J.H., et al. Predictors of 30-day mortality in patients with re- fractory cardiogenic shock following acute myocardial infarction despite a patent infarct artery. Am Heart J 2009;158:680—687.
Prondzinsky R., Hirsch K., Wachsmuth L., et al. Vasopressors for acute myocardial infarction complicated by cardiogenic shock. Med Klin Intensivmed Notfmed 2017 Dec 4 [Epub ahead of print].
Moller M.H., Claudius C., Junttila E., et al. Scandinavian SSAI clinical practice guideline on choice of first-line vasopressor for patients with acute circulatory failure. Acta Anaesthesiol Scand 2016;60:1347—1366.
Gamper G., Havel C., Arrich J., et al. Vasopressors for hypotensive shock. Cochrane Database Syst Rev 2016;(2):CD003709.
De Backer D., Biston P., Devriendt J., et al. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 2010;362:779—789.
Lorusso R., Gelsomino S., Parise O., et al. Venoarterial extracorporeal membrane oxygenation for refractory cardiogenic shock in elderly patients: trends in application and outcome from the Extracorporeal Life Support Organization (ELSO) Registry. Ann Thorac Surg 2017;104:62—69.
Tarvasmaki T., Lassus J., Varpula M., et al. Current real-life use of vasopressors and inotropes in cardiogenic shock—adrenaline use is associated with excess organ injury and mortality. Crit Care 2016;20:208.
Sakr Y., Reinhart K., Vincent J.L., et al. Does dopamine administration in shock influence outcome? Results of the Sepsis Occurrence in Acutely Ill Patients (SOAP) Study. Crit Care Med 2006;34:589—597.
Thiele H., Zeymer U., Neumann F.J., et al. Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med 2012;367:1287—1296.
Annane D., Vignon P., Renault A., et al. Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial. Lancet 2007;370:676—684.
Nativi-Nicolau J., Selzman C.H., Fang J.C., Stehlik J. Pharmacologic therapies for acute cardiogenic shock. Curr Opin Cardiol 2014;29:250—257.
15.Beurton A., Ducrocq N., Auchet T., et al. Beneficial effects of norepinephrine alone on cardiovascular function and tissue oxygenation in a pig model of cardiogenic shock. Shock 2016;46:214—218.
Perez P., Kimmoun A., Blime V., Levy B. Increasing mean arterial pressure in cardiogenic shock secondary to myocardial infarction: effects on hemodynamics and tissue oxygenation. Shock 2014;41:269—274.
Levy B., Mansart A., Montemont C., et al. Myocardial lactate deprivation is associated with decreased cardiovascular performance, decreased myocardial energetics, and early death in endotoxic shock. Intensive Care Med 2007;33:495—502.
Schreiber W., Herkner H., Koreny M., et al. Predictors of survival in unselected patients with acute myocardial infarction requiring continuous catecholamine support. Resuscitation 2002;55:269—276.
van Diepen S., Katz J.N., Albert N.M., et al. Contemporary management of cardiogenic shock: a scientific statement from the American Heart Association. Circulation 2017;136:e232—268.
Kolte D., Khera S., Aronow W.S., et al. Trends in incidence, management, and outcomes of cardiogenic shock complicating ST-elevation myocardial Infarction in the United States. J Am Heart Assoc 2014;3:e000590.
Goldberg R.J., Samad N.A., Yarzebski J., et al. Temporal trends in cardiogenic shock complicating acute myocardial infarction. N Engl J Med 1999;340:1162—1168.
Killip T. III, Kimball J.T. Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients. Am J Cardiol 1967; 20:457—464.
Hochman J.S., Sleeper L.A., Webb J.G., et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock. N Engl J Med 1999;341:625—634.
Wayangankar S.A., Bangalore S., McCoy L.A., et al. Temporal trends and outcomes of patients undergoing percutaneous coronary interventions for cardiogenic shock in the setting of acute myocardial infarction: a report from the CathPCI Registry. J Am Coll Cardiol Intv 2016;9:341—351.
Levy B., Perez P., Perny J., et al. Comparison of norepinephrine- dobutamine to epinephrine for hemodynamics, lactate metabolism, and organ function variables in cardiogenic shock. A prospective, randomized pilot study. Crit Care Med 2011;39:450—455.
Totaro R.J., Raper R.F. Epinephrine-induced lactic acidosis following cardiopulmonary bypass. Crit Care Med 1997;25:1693—1699.
De Backer D., Creteur J., Silva E., Vincent J.L. Effects of dopamine, norepinephrine, and epinephrine on the splanchnic circulation in septic shock: which is best? Crit Care Med 2003;31:1659—1667.
van Diepen S. The clinical implication of this finding is that epinephrine treatment may confound the interpretation of lactate clearance as a marker of restoration of systemic perfusion. Norepinephrine as a First-Line Inopressor in Cardiogenic Shock: Oversimplification or Best Practice? J Am Coll Cardiol 2018;72:183—186.
Freis E.D., Schnaper H.W., Johnson R..L, Schreiner G.E. Hemodynamic alterations in acute myocardial infarction. I. Cardiac output, mean arterial pressure, total peripheral resistance, cen- tral and total blood volumes, venous pressure and average circulation time. J Clin Invest 1952;31:131—140.
Jacobs A.K., Leopold J.A., Bates E., et al. Cardiogenic shock caused by right ventricular infarction: a report from the SHOCK registry. J Am Coll Cardiol 2003;41:1273—1279.
Menon V., Slater J.N., White H.D., et al. Acute myocardial infarction complicated by systemic hypoperfusion without hypotension: report of the SHOCK trial registry. Am J Med 2000;108:374—380.
Kohsaka S., Menon V., Lowe A.M., et al. Systemic inflammatory response syndrome after acute myocardial infarction complicated by cardiogenic shock. Arch Intern Med 2005;165:1643—1650.